Ispecimen INC. (ISPC) — 8-K Filings

All 8-K filings from Ispecimen INC.. Browse 35 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (35)

iSpecimen Inc. Files 8-K Report — Dec 1, 2025 Risk: low
On November 28, 2025, iSpecimen Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific financial transacti
iSpecimen Inc. Faces Delisting Concerns — Nov 21, 2025 Risk: high
iSpecimen Inc. filed an 8-K on November 21, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported wa
8-K Filing — Nov 7, 2025
8-K Filing — Nov 3, 2025
iSpecimen Inc. Files 8-K: Regulation FD Disclosure & Exhibits — Sep 4, 2025 Risk: low
On September 4, 2025, iSpecimen Inc. filed a Form 8-K to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
iSpecimen Inc. Files 8-K: Regulation FD Disclosure & Exhibits — Aug 21, 2025 Risk: low
On August 21, 2025, iSpecimen Inc. filed a Form 8-K to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain spec
iSpecimen Inc. Files 8-K Report — Aug 7, 2025 Risk: low
On August 7, 2025, iSpecimen Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits, with no spe
iSpecimen Inc. Files 8-K: Material Agreement and Financials — Aug 5, 2025 Risk: medium
On July 31, 2025, iSpecimen Inc. entered into a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements with
iSpecimen Inc. Files 8-K for Material Agreement — Jul 25, 2025 Risk: medium
On July 23, 2025, iSpecimen Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures and financial
iSpecimen Inc. Files 8-K with Corporate Updates — Jul 10, 2025 Risk: low
On July 9, 2025, iSpecimen Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws and the filing of Financial Statements and E
iSpecimen Inc. Files 8-K: Board and Compensation Updates — Jun 24, 2025 Risk: medium
On June 18, 2025, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election o
iSpecimen Inc. Faces Delisting Concerns — Jun 5, 2025 Risk: high
iSpecimen Inc. filed an 8-K on June 5, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a transfer of listi
iSpecimen Inc. Appoints BDO USA, LLP as New Auditor — Mar 11, 2025 Risk: medium
On March 7, 2025, iSpecimen Inc. filed an 8-K report to disclose changes in its certifying accountant. The company has appointed BDO USA, LLP as its new indepen
iSpecimen Inc. Reports Board and Executive Changes — Feb 24, 2025 Risk: medium
On February 19, 2025, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the depart
iSpecimen Inc. Files 8-K Report — Jan 16, 2025 Risk: low
On January 16, 2025, iSpecimen Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating update
iSpecimen Inc. Reports Director Changes and Compensation Adjustments — Dec 30, 2024 Risk: medium
On December 27, 2024, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the depart
iSpecimen Inc. Appoints New CMO, Elects Director — Dec 20, 2024 Risk: low
On December 13, 2024, iSpecimen Inc. announced the appointment of Dr. Jonathan S. Roth as Chief Medical Officer and the election of Mr. David J. Miller to its B
iSpecimen Inc. Files 8-K Report — Dec 13, 2024 Risk: low
On December 13, 2024, iSpecimen Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updat
iSpecimen Appoints New CMO, Elects Director — Dec 12, 2024 Risk: low
On December 9, 2024, iSpecimen Inc. announced the appointment of Dr. Jonathan S. Roth as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its
iSpecimen Inc. Reports Director Changes and Compensation Adjustments — Nov 12, 2024 Risk: medium
On November 7, 2024, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in
iSpecimen Inc. Files 8-K with Material Agreement Details — Oct 31, 2024 Risk: medium
On October 29, 2024, iSpecimen Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financ
iSpecimen Inc. Files 8-K Report — Oct 2, 2024 Risk: low
On July 25, 2024, iSpecimen Inc. filed an 8-K report detailing an event under Regulation FD Disclosure and Other Events. The filing does not contain specific fi
iSpecimen Inc. Files 8-K: New Agreements & Executive Changes — Sep 25, 2024 Risk: medium
On September 19, 2024, iSpecimen Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also announced the depar
iSpecimen Inc. Files 8-K with Corporate Updates — Sep 11, 2024 Risk: medium
On September 11, 2024, iSpecimen Inc. filed an 8-K report detailing material modifications to the rights of its security holders and amendments to its articles
iSpecimen Inc. Files 8-K on Financials — Aug 6, 2024 Risk: low
On August 6, 2024, iSpecimen Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and
iSpecimen Inc. Reports Board Changes and Shareholder Votes — Jul 22, 2024 Risk: medium
On July 17, 2024, iSpecimen Inc. announced changes to its board of directors, including the election of new directors and the departure of existing ones. The co
iSpecimen Inc. Reports Board and Executive Changes — Jul 8, 2024 Risk: medium
On July 5, 2024, iSpecimen Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the departure o
iSpecimen Inc. Files 8-K: Material Agreements Entered and Terminated — Jul 3, 2024 Risk: medium
On June 28, 2024, iSpecimen Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The company, incorporated in
iSpecimen Inc. Closes $1.5M Private Placement — May 17, 2024 Risk: medium
On May 16, 2024, iSpecimen Inc. announced the closing of its previously disclosed private placement of common stock. The company raised approximately $1.5 milli
iSpecimen Inc. Files 8-K on Financials — May 7, 2024 Risk: low
On May 7, 2024, iSpecimen Inc. filed an 8-K report detailing its financial condition and operations. The filing includes financial statements and exhibits, prov
iSpecimen Inc. Faces Delisting Concerns — Apr 11, 2024 Risk: high
iSpecimen Inc. filed an 8-K on April 11, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The earliest event reported was on
iSpecimen Inc. Elects New Directors, Adjusts Executive Pay — Mar 26, 2024 Risk: medium
On March 21, 2024, iSpecimen Inc. announced changes to its board of directors and executive compensation. Specifically, the company elected two new directors, D
iSpecimen Inc. Files 8-K Report — Mar 14, 2024 Risk: low
On March 14, 2024, iSpecimen Inc. filed an 8-K report detailing its financial condition and operations. The filing includes financial statements and exhibits, b
iSpecimen Inc. Files 8-K for Material Agreement — Mar 5, 2024 Risk: medium
On March 5, 2024, iSpecimen Inc. filed an 8-K report detailing an entry into a material definitive agreement. The filing also includes financial statements and
iSpecimen Reports Entry & Termination of Material Agreements — Feb 15, 2024 Risk: medium
iSpecimen Inc. filed an 8-K on February 15, 2024, reporting events that occurred on February 13, 2024. The filing indicates both the entry into and termination

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX